Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach
Biotricity (OTCQB:BTCY), a Technology-as-a-Service healthcare solutions provider, reported strong financial results for FY2025. The company achieved 14.3% revenue growth to $13.8 million, with significant margin improvement to 76.6% from 69.3% in the previous year.
Key highlights include a 24.5% reduction in operating expenses, negative EBITDA improvement of 63.9% to $3.2 million, and the company's first-ever positive Adjusted EBITDA of $438,260 in Q4-FY25. Recurring Technology Fees grew 12% YOY to $12.6 million, representing over 10.5 times Device Sales revenue. The company secured strategic partnerships with GPOs representing 90% of US hospitals and is pursuing FDA clearance for its AI clinical model.
Biotricity (OTCQB:BTCY), fornitore di soluzioni sanitarie Technology-as-a-Service, ha riportato risultati finanziari solidi per l'anno fiscale 2025. L'azienda ha registrato una crescita dei ricavi del 14,3% raggiungendo 13,8 milioni di dollari, con un significativo miglioramento del margine, salito al 76,6% rispetto al 69,3% dell'anno precedente.
Tra i punti salienti, una riduzione delle spese operative del 24,5%, un miglioramento del EBITDA negativo del 63,9% a 3,2 milioni di dollari, e il primo Adjusted EBITDA positivo della società pari a 438.260 dollari nel quarto trimestre dell'anno fiscale 2025. Le Commissioni Tecnologiche Ricorrenti sono cresciute del 12% su base annua, raggiungendo 12,6 milioni di dollari, superando di oltre 10,5 volte i ricavi derivanti dalla vendita di dispositivi. L'azienda ha siglato partnership strategiche con GPO che rappresentano il 90% degli ospedali statunitensi e sta perseguendo l'approvazione FDA per il suo modello clinico basato sull'IA.
Biotricity (OTCQB:BTCY), proveedor de soluciones de salud Technology-as-a-Service, reportó sólidos resultados financieros para el año fiscal 2025. La compañía logró un crecimiento de ingresos del 14,3% alcanzando 13,8 millones de dólares, con una mejora significativa en el margen al 76,6% desde el 69,3% del año anterior.
Entre los aspectos destacados se incluyen una reducción del 24,5% en gastos operativos, una mejora del EBITDA negativo del 63,9% hasta 3,2 millones de dólares, y el primer EBITDA Ajustado positivo de la empresa de 438.260 dólares en el cuarto trimestre del año fiscal 2025. Las Tarifas Tecnológicas Recurrentes crecieron un 12% interanual hasta 12,6 millones de dólares, representando más de 10,5 veces los ingresos por ventas de dispositivos. La empresa aseguró asociaciones estratégicas con GPOs que representan el 90% de los hospitales de EE.UU. y está buscando la aprobación de la FDA para su modelo clínico basado en IA.
Biotricity (OTCQB:BTCY)는 서비스형 기술(Technology-as-a-Service) 헬스케어 솔루션 제공업체로서 2025 회계연도에 강력한 재무 실적을 보고했습니다. 회사는 매출이 14.3% 증가하여 1,380만 달러를 기록했으며, 마진은 전년도의 69.3%에서 76.6%로 크게 개선되었습니다.
주요 내용으로는 운영비용 24.5% 감소, EBITDA 적자 개선 63.9%로 320만 달러, 그리고 2025 회계연도 4분기에 회사 최초의 조정 EBITDA 흑자 438,260달러 달성이 포함됩니다. 반복 기술 수수료는 전년 대비 12% 증가한 1,260만 달러로, 장치 판매 수익의 10.5배 이상을 차지합니다. 회사는 미국 병원의 90%를 대표하는 GPO와 전략적 파트너십을 체결했으며 AI 임상 모델에 대한 FDA 승인도 추진 중입니다.
Biotricity (OTCQB:BTCY), fournisseur de solutions de santé en mode Technology-as-a-Service, a publié de solides résultats financiers pour l'exercice 2025. La société a enregistré une croissance du chiffre d'affaires de 14,3% atteignant 13,8 millions de dollars, avec une amélioration significative de la marge à 76,6% contre 69,3% l'année précédente.
Les points clés incluent une réduction des dépenses opérationnelles de 24,5%, une amélioration de l'EBITDA négatif de 63,9% à 3,2 millions de dollars, et le premier EBITDA ajusté positif de l'entreprise s'élevant à 438 260 dollars au quatrième trimestre de l'exercice 2025. Les frais technologiques récurrents ont augmenté de 12% en glissement annuel pour atteindre 12,6 millions de dollars, représentant plus de 10,5 fois les revenus des ventes de dispositifs. La société a conclu des partenariats stratégiques avec des GPO représentant 90% des hôpitaux américains et poursuit l'obtention de l'approbation de la FDA pour son modèle clinique basé sur l'IA.
Biotricity (OTCQB:BTCY), ein Anbieter von Healthcare-Lösungen als Technology-as-a-Service, meldete starke Finanzergebnisse für das Geschäftsjahr 2025. Das Unternehmen erzielte ein Umsatzwachstum von 14,3% auf 13,8 Millionen US-Dollar, mit einer deutlichen Margenverbesserung auf 76,6% gegenüber 69,3% im Vorjahr.
Zu den wichtigsten Highlights zählen eine Reduzierung der Betriebskosten um 24,5%, eine Verbesserung des negativen EBITDA um 63,9% auf 3,2 Millionen US-Dollar sowie das erste positive bereinigte EBITDA des Unternehmens in Höhe von 438.260 US-Dollar im vierten Quartal des Geschäftsjahres 2025. Die wiederkehrenden Technologiegebühren wuchsen 12% im Jahresvergleich auf 12,6 Millionen US-Dollar und übersteigen damit das 10,5-fache der Umsätze aus Geräteverkäufen. Das Unternehmen sicherte sich strategische Partnerschaften mit GPOs, die 90% der US-Krankenhäuser vertreten, und strebt die FDA-Zulassung für sein KI-basiertes klinisches Modell an.
- First-ever positive Adjusted EBITDA of $438,260 in Q4-FY25
- Revenue growth of 14.3% to $13.8 million in FY25
- Significant margin improvement to 76.6% from 69.3% YOY
- Operating expenses reduced by 24.5% YOY
- Negative EBITDA improved by $5.7 million (63.9% reduction)
- Strategic partnerships secured with GPOs covering 90% of US hospitals
- Strong recurring revenue with Technology Fees at 12% YOY growth
- Net loss of $11.9 million in FY25, despite 20% improvement YOY
- Still operating at negative EBITDA of $3.2 million annually
- FDA clearance for AI clinical model still pending
Insights
Biotricity shows remarkable financial turnaround with first-ever positive Adjusted EBITDA, indicating imminent profitability after years of investment.
Biotricity's FY25 results demonstrate a company approaching an inflection point on its path to profitability. The 14.3% year-over-year revenue growth to
The standout metric is the achievement of
The recurring technology fees, which grew
Strategic partnerships with GPOs giving access to
- FY25 revenue up
14.3% YOY - FY25 margins improvement of
8.9% to76.6% , from69.3% in the prior year; Q4-FY25 margins improved to80.4% as margin expansion forecasted to continue - FY25 operating expenses lower by
24.5% YOY - Negative EBITDA reduced by
$5.7 million to$3.2 million – an improvement of63.9% - Positive Adjusted EBITDA of
$438,260 in the fourth quarter of FY25 – first time in Company’s history, highlighting Company’s ability to achieve breakeven and EBITDA positive in the early part of its FY26
REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chronic disease, and lifestyle management solutions for healthcare providers and consumers, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2025.
Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, said, "Fiscal 2025 has been another year of massive transformation for Biotricity. We’ve further utilized workflow automation, AI, and continued technological enhancements to drive substantial improvements in operational expenses, margin expansion, and revenue growth. This year, we demonstrated our ability to scale efficiently while maintaining high-quality service, bringing us to the doorstep of EBITDA breakeven and long-term profitability.
The expansion of our Cardiac AI Cloud platform, supported by strategic partnerships with other industry leaders, showcases our commitment to revolutionizing medical diagnostics, chronic care management, and consumer healthcare. Leveraging over a trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability and growth, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months.
Collaborative partnerships established during fiscal 2025 and 2026 have positioned us to capitalize on expansive market channels, providing access to approximately
FY25 Financial Highlights
- Revenue increased
14.3% to$13.8 million compared with$12.1 million in FY24 - Gross margin was
76.6% for the fiscal year ended March 31, 2025, as compared to69.3% in FY24; this was the result of expansion in recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring cost structure. - Net loss decreased
20% YOY to$11.9 million , or$0.56 per share, from a net loss of$14.9 million , or$1.66 per share, in FY24
Q4-FY25 Financial Highlights
- Revenue increased
16.5% to$3.7 million compared with$3.5 million in Q4 FY24 - Gross margin was
80.4% for the three months ended March 31, 2025, as compared to71.5% in the corresponding prior year quarter - Net loss decreased
54% YOY to$2 million , or$0.08 per share, from a net loss of$4.4 million , or$0.47 per share, in Q4-FY24
Operating Highlights for FY25
- FY25 recurring (TaaS) Technology Fees rose a robust
12% YOY to$12.6 million , representing over 10.5 times Device Sales revenue - Company continues to maintain an impressive track record of customer retention, driven by high-quality customer and provider friendly support services, emphasis on accurate diagnostics, and user-friendly solutions. Developed a range of state-of-the-art products to service a total addressable market of
$35 billion . - Secured strategic alliances with three of the top GPOs representing
90% of all hospitals in the US - Arrived at positive cash flows by growing subscription-based revenues, improving margins, and leveraging automation and experience to increase efficiencies of SG&A.
Full details of the Company's financial results will be filed with the SEC on Form 10-K and available by visiting www.sec.gov.
Financial Results and Business Update Conference Call
Management will host a conference call on Friday July 18, 2025 at 4:45 p.m. ET to discuss its financial results for fiscal year 2025 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: https://www.biotricity.com/investors/
Event: Biotricity Fourth Quarter and FY 2025 Financial Results and Business Update Call
Date: Friday, July 18, 2025
Time: 4:45pm ET (1:45pm PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1727799&tp_key=558b5c669d
Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.
A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at https://www.biotricity.com/investors/.
Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13754989
Expiration: Friday, August 1, 2025 at 11:59 PM ET
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Non-GAAP Measures
Non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. It is management’s intent to provide non-GAAP financial information to enhance the understanding of Biotricity’s GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance.
| EBITDA and Adjusted EBITDA | ||||||||||||||||
| Year ended March 31, 2025 | Year ended March 31, 2024 | 3 months ended March 31, 2025 | 3 months ended March 31, 2024 | |||||||||||||
| $ | $ | $ | $ | |||||||||||||
| Net loss attributable to common stockholders | (11,942,000 | ) | (14,928,960 | ) | (2,022,133 | ) | (4,400,104 | ) | ||||||||
| Add: | ||||||||||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Interest expense | 3,262,038 | 3,018,803 | 891,752 | 814,943 | ||||||||||||
| Accretion and amortization expenses | 1,945,769 | 2,178,873 | 165,560 | 598,063 | ||||||||||||
| Preferred stock dividends | 3,520,821 | 834,677 | 86,396 | 217,634 | ||||||||||||
| EBITDA | (3,213,372 | ) | (8,896,607 | ) | (878,425 | ) | (2,769,464 | ) | ||||||||
| Add (Less) | ||||||||||||||||
| Share based compensation (1) | 1,420,121 | 1,025,930 | 1,247,319 | 481,275 | ||||||||||||
| Other (income)/loss (2) | 78,569 | 102,607 | (49,405 | ) | (16,334 | ) | ||||||||||
| Gain (loss) upon convertible promissory notes conversion and redemption (2) | 141267 | (18,539 | ) | (8,391 | ) | (3,259 | ) | |||||||||
| Fair value change on derivative liabilities (2) | 595,442 | (9,777 | ) | 127,162 | (253,791 | ) | ||||||||||
| Adjusted EBITDA | (977,973 | ) | (7,796,386 | ) | 438,260 | (2,561,573 | ) | |||||||||
| Weighted average number of common shares outstanding | 21,524,884 | 8,991,766 | 21,524,884 | 9,441,667 | ||||||||||||
| Adjusted Loss per Share, Basic and Diluted | (0.045 | ) | (0.867 | ) | 0.017 | (0.271 | ) | |||||||||
(1) Share based compensation is a non-cash item
(2) These items relate to financing transactions and do not reflect the Company’s core operating activities
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts
Investor Relations
Biotricity Investor Relations
Investors@biotricity.com
SOURCE: Biotricity, Inc.
FAQ
What were Biotricity's (BTCY) key financial results for fiscal year 2025?
How much did Biotricity (BTCY) reduce its net loss in FY 2025?
What was Biotricity's (BTCY) recurring revenue performance in FY 2025?
What strategic partnerships did Biotricity (BTCY) secure in FY 2025?
What were Biotricity's (BTCY) Q4 FY25 financial highlights?
